You are here: Industry Insights > Kisqali

News List

Kisqali receives FDA Breakthrough Therapy for advanced breast cancer europeanpharmaceuticalreview
January 04, 2018
Kisqali receives FDA Breakthrough Therapy designation for initial endocrine-based treatment of pre- or perimenopausal women with HR+/HER2- advanced or metastatic breast cancer…
NICE recommends Kisqali as a cost-effective treatment for advanced breast cancer europeanpharmaceuticalreview
November 17, 2017
NICE recommends Kisqali as a cost-effective treatment option for postmenopausal women within England and Wales with advanced breast cancer…
EC approves Novartis’ breast cancer drug Kisqali expressbpd
August 28, 2017
Swiss drugmaker Novartis’ Kisqali (ribociclib) has received approval from the European Commission (EC) as a first-line treatment for advanced breast cancer.
Novartis breast cancer drug Kisqali wins EU approval pharmatimes
August 25, 2017
Novartis has announced the launch of its new breast cancer drug Kisqali in the UK today following a green light from European regulators.
Kisqali Receives EU Approval as First-Line Treatment for HR+/HER2- Advanced, Metastatic Breast Cance americanpharmaceuticalreview
August 25, 2017
Novartis announced that the European Commission (EC) approved Kisqali (ribociclib) in combination with an aromatase inhibitor for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2
New Novartis rival Kisqali hasn't slowed down Pfizer's Ibrance—at least not yet fiercepharma
August 08, 2017
Pfizer's Ibrance topped second-quarter consensus numbers in both the U.S. and the rest of the world
FDA Approves Kisqali drugs.com
March 14, 2017
The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib, formerly known as LEE011) in combination with an aromatase inhibitor as initial endocrine-based therapy...

Previous page 1 2 Next page